HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
liblomycin
structure given in first source
Also Known As:
N(1)-(3-((3-(bis((3,4-bis(phenylmethoxy)phenyl)methyl)amino)propyl)methylamino)propyl)bleomycinamide; NK 313; NK313; libromycin
Networked:
12
relevant articles (
1
outcomes,
4
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Carbohydrates: 22023
Glycoconjugates: 1353
Glycopeptides: 1928
Bleomycin: 9833
liblomycin: 12
Amino Acids, Peptides, and Proteins: 1
Peptides: 82426
Glycopeptides: 1928
Bleomycin: 9833
liblomycin: 12
Related Diseases
1.
Leukemia P388
02/01/1990 - "
In comparison to bleomycin which was without any antitumor efficacy against P388 leukemia, a dose of 10 mg/kg Liblomycin administered on a daily schedule for 10 consecutive days resulted in a significant increase in animal survival (% T/C of 190).
"
2.
Neoplasms (Cancer)
04/01/1991 - "
These differences suggest that NK313 might be of value to treat PEP-insensitive tumor cells.
"
03/01/1989 - "
These data represent the first comparison of liblomycin to bleomycin against a spectrum of fresh human tumors using a stem cell assay technique.
"
01/01/1987 - "
Liblomycin, derivative of Bleomycin having a lipophyllic characteristics, was developed since it showed in animal studies a lower pulmonary toxicity than that of Peplomycin and broader anti-tumor spectrum.
"
03/01/1989 - "
The relative activity of liblomycin versus that of bleomycin and tallysomycin S10b varied with individual tumors tested.
"
03/01/1989 - "
When tested against fresh human tumors at equally myelotoxic IC90 concentrations, bleomycin and tallysomycin S10b (nonmyelotoxic compounds) both achieved 90% growth inhibition of all tumors, while liblomycin (a myelotoxic compound) produced an IC90 inhibition in 69% of all tumors.
"
3.
Ascites
01/01/1992 - "
In contrast, ascites tumour growth is completely inhibited by liblomycin and appears to be at least partly macrophage-mediated because the antitumour effect can be significantly inhibited by carageenan.
"
04/01/1991 - "
The cell kill kinetics of NK313 on rat ascites hepatoma AH66 were compared with those of PEP.
"
01/01/1992 - "
This study also shows that although liblomycin decreases spleen cell cytokine production and is less effective than bleomycin against subcutaneous tumour, as we have previously reported, the antitumour drug activates peritoneal macrophages and, compared to bleomycin, has a remarkable therapeutic effect on rat ascites tumour.
"
4.
Thrombocytopenia (Thrombopenia)
02/01/1990 - "
Liblomycin, in contrast to bleomycin, produced mild and transient leukopenia and thrombocytopenia suggesting that this toxicity will be a limiting one in future clinical trials.
"
5.
Lymphoma (Lymphomas)
01/01/1993 - "
Phase II study of NK313 in malignant lymphomas: an NK313 Malignant Lymphoma Study Group trial.
"
01/01/1993 - "
We concluded that liblomycin demonstrated significant antitumor activity against malignant lymphomas.
"
01/01/1993 - "
In the present phase II study, patients with malignant lymphomas received liblomycin at 80 or 100 mg/m2 by intravenous infusion over 15 min once a week for 4 weeks.
"
Related Drugs and Biologics
1.
Bleomycin (Blenoxane)
2.
Therapeutic Uses
3.
Peplomycin
4.
Cytokines
5.
liblomycin
6.
Platinum
7.
Cisplatin (Platino)
8.
NK 121
9.
Menogaril
10.
Doxorubicin (Adriamycin)
Related Therapies and Procedures
1.
Intravenous Infusions
2.
Injections